No Data
Hundred Li Tianheng (688506): Innovative pipeline progressing rapidly, actively laying out internationalization.
The company released the third quarter report of 2024: In the first three quarters of 2024, the company achieved revenue of 5.663 billion yuan, an increase of 1,399.22% compared to the same period last year; the net income attributable to the shareholders of the listed company is 40.
Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Report for the third quarter of 2024
Baolitianheng (688506.SH) released its performance for the first three quarters, with a net income of 4.065 billion yuan.
Bailitienheng (688506.SH) released the third quarter report for 2024, with the company's revenue for the first three quarters reaching 56...
Bailitianheng (688506.SH): The net income for the first three quarters was 4.065 billion yuan.
GeLongHui reported its third quarter results on October 28. The revenue for the first three quarters was 5.66 billion yuan, a year-on-year increase of 1399.22%. The net income was 4.065 billion yuan, with a non-net profit of 4.04 billion yuan, and basic earnings per share of 10.14 yuan.
Bailitianheng (688506): The company received intensive catalysis, and the clinical trials in China and the United States continue to advance.
Event 1: The company's core pipeline EGFR*HER3 dual antibodies ADC BL-B01D1 continue to make progress in clinical trials in China and the United States. We believe that its subsequent clinical development and market launch process are promising, and we are bullish on 01D1 moving to the frontline.
No Data
No Data